+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 50 μg, Lane 1-2: Human fetal liver tissue, A549 cells, Primary antibody: P00791(GC Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P00791(GC Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P00791(GC Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

GC antibodies, also known as anti-glomerular basement membrane (anti-GBM) antibodies, are autoantibodies targeting type IV collagen in the basement membranes of glomeruli and alveoli. First identified in the 1960s, these antibodies are primarily associated with Goodpasture syndrome, a rare autoimmune disorder characterized by rapidly progressive glomerulonephritis and pulmonary hemorrhage. The pathogenic antibodies bind to the non-collagenous (NC1) domain of the α3 chain of type IV collagen, triggering complement activation and inflammatory damage.

Genetic and environmental factors, such as HLA-DR15 susceptibility and hydrocarbon exposure, may contribute to disease onset. Diagnosis relies on detecting circulating anti-GBM antibodies via ELISA or immunofluorescence, alongside kidney biopsy showing linear IgG deposits. While historically fatal, advancements in immunosuppressive therapies (e.g., cyclophosphamide, corticosteroids) and plasma exchange have significantly improved survival rates.

Interestingly, low titers of anti-GBM antibodies occasionally occur without clinical disease, suggesting complex immune regulation. Research continues to explore epitope-specific antibody profiles and novel biologics for refractory cases. GC antibody-mediated diseases exemplify the interplay between autoimmunity and organ-specific pathology, emphasizing early detection and targeted intervention.